Potent Anti-Inflammatory Activity of Pyrenocine A Isolated from the Marine-Derived Fungus *Penicillium paxilli* Ma(G)K

Thaís Regina Toledo,1 Naiara N. Dejani,1,2 Luis Gustavo Silva Monnazzi,1 Miriam H. Kossuga,3 Roberto G. S. Berlinck,3 Lara D. Sette,4 and Alexandra I. Medeiros1

1 Departamento de Ciências Biológicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio de Mesquita Filho", 14801-902 Araraquara, SP, Brazil
2 Faculdade de Medicina Ribeirão Preto, Universidade de São Paulo, 14049-900 Ribeirão Preto, SP, Brazil
3 Instituto de Química de São Carlos, Universidade de São Paulo, CP 780, 13560-970 São Carlos, SP, Brazil
4 Departamento de Bioquímica e Microbiologia, Instituto de Biociências, Universidade Estadual Paulista "Júlio de Mesquita Filho", 13506-900 Rio Claro, SP, Brazil

Correspondence should be addressed to Alexandra I. Medeiros; meeirosai@fcfar.unesp.br

Received 15 August 2013; Revised 12 November 2013; Accepted 19 November 2013; Published 19 January 2014

Academic Editor: Chiara De Luca

Copyright © 2014 Thaís Regina Toledo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Very little is known about the immunomodulatory potential of secondary metabolites isolated from marine microorganisms. In the present study, we characterized pyrenocine A, which is produced by the marine-derived fungus *Penicillium paxilli* Ma(G)K and possesses anti-inflammatory activity. Pyrenocine A was able to suppress, both pretreatment and posttreatment, the LPS-induced activation of macrophages via the inhibition of nitrite production and the synthesis of inflammatory cytokines and PGE2. Pyrenocine A also exhibited anti-inflammatory effects on the expression of receptors directly related to cell migration (Mac-1) as well as costimulatory molecules involved in lymphocyte activation (B7.1). Nitrite production was inhibited by pyrenocine A in macrophages stimulated with CpG but not Poly I:C, suggesting that pyrenocine A acts through the MyD88-dependent intracellular signaling pathway. Moreover, pyrenocine A is also able to inhibit the expression of genes related to NFκB-mediated signal transduction on macrophages stimulated by LPS. Our results indicate that pyrenocine A has promissory anti-inflammatory properties and additional experiments are necessary to confirm this finding in vivo model.

1. Introduction

Inflammation is a complex host immune system response to stimuli such as microbial infection, endotoxin exposure, burns, and tissue injury. Resident macrophages are the first line of defense against insults and play a key role in the development of inflammation [1, 2]. These phagocytes have a variety of receptors on their surface membrane, termed Pattern Recognition Receptors (PRRs), which facilitate interactions with many molecules present on pathogens, known as PAMPs (pathogen-associated molecular patterns). PRRs such as TLRs (Toll-like receptors) interact with PAMPs that are present on bacteria, viruses, parasites, and fungi, and these interactions play a key role in the activation of phagocytic cells. Lipopolysaccharide (LPS), which is produced by Gram-negative bacteria, binds with a TLR complex composed of CD14/LBP/TLR [1, 2], resulting in the activation of a complex biochemical cascade that promotes the recruitment of MyD88, the activation of protein kinases such as IRAK, recruitment of the adaptor protein TRAF6, and the subsequent activation of NFκB and AP-1 in the nucleus [3]. Cytosolic IκB is only phosphorylated after stimulation by lipopolysaccharide (LPS), resulting in the dissociation of the IκB complex and the translocation of NFκB into the nucleus, permitting interaction with the promoter regions of various genes that encode proinflammatory mediators [4]. Activation of these genes results in the excessive production of inflammatory cytokines including TNF-α, interleukin-1 (IL-1), and
IL-6 and other inflammatory mediators such as nitric oxide (NO) and lipid mediators, all of which play a deleterious role in acute and chronic inflammatory diseases such as atherosclerosis and arthritis [5]. In particular, prostaglandin E2 (PGE2) is a major inflammatory lipid mediator involved in the pathogenesis of chronic inflammatory diseases such as rheumatoid arthritis [6]. PGE2 synthesis occurs when there are disturbances in the cell membrane, leading to increased intracellular calcium and the translocation of cytosolic phospholipase A2 (cPLA2) to the nuclear membrane, followed by the release of arachidonic acid (AA) from phospholipids in the nuclear membrane. The released AA can be converted into PGH2 in the presence of COX-1 (an enzyme constitutively expressed in different cell types) and COX-2 (an inducible enzyme) and then through the action of various prostaglandin synthases to generate different classes of PGs. PGE2 is a key lipid mediator synthesized by macrophages and other cell types in the presence of LPS [7]. In addition to promoting edema, PGE2 can indirectly act to modulate the synthesis of different cytokines and chemokines [8, 9]. PGE2 plays a role in the development of inflammation at sites of tissue injury by interacting with EP1/EP3 and therefore is a prime target for potential anti-inflammatory drugs in the treatment of acute and chronic inflammatory diseases [10].

Marine microorganisms are unique biological sources of potently active secondary metabolites, which have been investigated over the last 20 years with the goal of discovering new drugs [11–13]. Marine fungi are considered to be particularly rich metabolic sources of active natural products [12–16]. Recently, we isolated pyrenocine A from the marine-derived fungus Penicillium paxilli Ma(G)K. Pyrenocine A was previously reported to be an antimalarial and a cytotoxic immunecells. mechanismsthroughwhichthisfungalmetabolitecanacton potential of pyrenocine A and to elucidate the possible

2.1. Isolation and Identification of Pyrenocine A. Pyrenocine A was previously obtained from the growth culture medium of the marine-derived fungus P. paxilli Ma(G)K, which was isolated from the sponge Mycale angulosa [18]. Briefly, P. paxilli Ma(G)K was inoculated in 500 mL Schott flasks, each containing 200 mL of 2% malt extract medium. Fungal growth occurred with shaking (100 rpm) at 25 °C for seven days. At the end of the growth period, 200 mL of ethyl acetate (EtOAc) was added to each flask. The culture media mixture containing mycelia and EtOAc was left shaking at 100 rpm for 24 h at 25 °C. Then, the mixture was filtered through Celite. The EtOAc fraction was separated by liquid-liquid partitioning. Evaporation of the EtOAc fraction yielded 400 mg of an extract, which was separated by chromatography on a cyanopropyl-bonded silica-gel cartridge (2 g; eluents: 100% CH₂Cl₂, 100% EtOAc, and 100% MeOH). The CH₂Cl₂ fraction (130 mg) was separated by HPLC using a C₁₈ reversed phase column Inertsil ODS-3 (4.6 × 250 mm; 5 μm) with a gradient of 1:1 MeOH : MeCN in H₂O plus 0.1% formic acid (flow rate: 1.0 mL/min; detection: UV absorption at λ_max 254 nm). Pyrenocine A (42.7 mg) was identified by analyzing the spectroscopic data and comparing them with the data in the literature [18].

2.2. Cell Line Maintenance. The RAW 264.7 cell line, which was used in all in vitro experiments, was obtained from the Rio de Janeiro Cell Bank (BCRJ/UFRJ). The RAW 264.7 cell line is a mouse leukemic monocyte-macrophage cell line. For cytotoxicity assays and anti-inflammatory activity assays, cells were thawed and expanded into cell culture flasks in DMEM containing 10% FBS (fetal bovine serum) and gentamicin (1:1000) at 37 °C in an incubator with a humidified atmosphere containing 5% CO₂, following the American Type Culture Collection (ATCC) guidelines.

2.3. Cell Stimulation: Pretreatment and Posttreatment Protocol, Cytotoxicity Assays, and Cell Death. RAW 264.7 cells (5 × 10⁴) were distributed in 96-well plates and used for pretreatment and posttreatment assays. Lymphophilized pyrenocine A was reconstituted in DMSO and then diluted in DMEM-I (media) for 2h, and stimuli with LPS, CpG, or Poly I:C (1 μg/mL) for 18 h at 37 °C. Posttreatment protocol: cells were incubated with LPS, CpG, or Poly I:C (1 μg/mL) for 2 h, and then pyrenocine A was added to the cell culture (3.75 to 0.11 μM) for 18 h at 37 °C. The supernatants were collected and stored at −80 °C until quantification of soluble mediators was performed.

The cytotoxicity was evaluated by MTT and Alamar Blue assay and cells death by Annexin V/PI (BD Biosciences) as manufacturer’s recommendation.

2.4. Quantification of Nitrite. Nitrite levels in the culture supernatant samples were measured with Griess reagent as previously described [19]. The absorbance of the samples was measured in a microplate reader with a 540 nm filter (Biotek, model 960).

2.5. Quantification of Cytokines and PGE2 Levels. Cytokine production by macrophages was quantitated from culture supernatants using an ELISA reader. Levels of IL-1β, IL-6, IL-10, IL-12, and TNF-α were determined using specific antibodies (purified and biotinylated) and recombinant cytokine standards following the manufacturer’s instructions (Optel B & D Systems, MN and PharMingen, San Diego, CA). PGE2 was measured in culture supernatants using the EIA kit for PGE2 with a monoclonal antibody according to the manufacturer’s instructions (Cayman Chemical Company).

2.6. Flow Cytometry. The expression of surface receptors (CD11b/CD18 and B71, B72) was determined after treating RAW 264.7 cells with pyrenocine A using both the pretreatment and posttreatment procedures as previously described. All samples were analyzed using a FACSCanto flow cytometer.
dent samples were analyzed based on the manufacturer's protocol. The resulting data from three independent experiments were measured in a 96-well (TaqMan express plate, Applied Biosystems 7500 Real Time PCR equipment. Selected target genes were analyzed using both the pretreatment and posttreatment protocols. The inhibitory effects of pyrenocine A on TNF-α were evident even at low concentrations and were more pronounced with the posttreatment protocol (Figure 2). The treatment of pyrenocine A alone has no stimulatory effect on RAW 264.7 cells; the amount of NO produced is the same as untreated cells (data not shown).

3.2. Pyrenocine A Can Inhibit TNF-α Production by Macrophages. Next, we evaluated whether pyrenocine A was also able to modulate cytokine production using both experimental approaches. As shown in Figure 3, macrophages secrete high levels of TNF-α in the presence of LPS compared to unstimulated cells (Figure 3). LPS-induced synthesis of these inflammatory cytokines was inhibited by pyrenocine A in a concentration-dependent manner with both the pretreatment and posttreatment protocols. The inhibitory effects of pyrenocine A on TNF-α synthesis were more evident when the pretreatment procedure was employed (Figure 3). However, treatment of macrophages with pyrenocine A in the presence of LPS did not modulate the synthesis of other inflammatory cytokines, including IL-1β, IL-6, and IL-12, and had low effect on the synthesis of IL-10 (data not shown).

3.3. Pyrenocine A Inhibits PGE2 Synthesis. The stimulation of macrophages with LPS induces the synthesis of lipid mediators such as PGE2, a major lipid inflammatory mediator involved in the pathogenesis of chronic inflammatory diseases such as rheumatoid arthritis [6]. Therefore, in addition to examining inflammatory cytokines and NO, we evaluated the ability of pyrenocine A to modulate the expression of PGE2 synthesis in macrophages stimulated with LPS. As shown in Figure 4, LPS stimulation induced the synthesis of high concentrations of PGE2 compared to unstimulated cells. Treatment with pyrenocine A using the pretreatment procedure inhibited the synthesis of PGE2 by approximately 30 to 50% compared to LPS alone (Figure 4(a)) and at higher concentration of pyrenocine A during the posttreatment (Figure 4(b)).

3.4. Inhibition of Cell Surface Receptors Involved in Cellular Adhesion and Activation by Pyrenocine A. During inflammation, surface molecules such as Mac-1 (CD11b/CD18)
Figure 2: Anti-inflammatory effects of pyrenocine A on the production of NO. Pretreatment procedure: cells were pretreated with different concentrations of pyrenocine A (3.75–0.11 μM) for 2 h and then stimulated with LPS (1 μg/mL) during 18 h. Posttreatment procedure: cells were stimulated with LPS (1 μg/mL) for 2 h and then pyrenocine A was added (3.75–0.11 μM) during 18 h. Afterwards, the supernatants were collected, and nitrite concentrations were determined using Griess reagent. Results indicate the mean ± SEM for six independent experiments performed in quadruplicate for each condition. *P < 0.05 versus medium (control), #P < 0.05 versus LPS (ANOVA followed by Bonferroni). ND = not detectable.

Figure 3: Anti-inflammatory effects of pyrenocine A on the production of TNF-α. (a) Pretreatment procedure: cells were pretreated with different concentrations of pyrenocine A (3.75–0.11 μM) for 2 h and then stimulated with LPS (1 μg/mL) during 18 h. (b) Posttreatment procedure: cells were stimulated with LPS (1 μg/mL) for 2 h and then pyrenocine A (3.75–0.11 μM) was added during 18 h. The supernatants were collected, and cytokine quantification was performed using an ELISA system. Results correspond to the mean ± SEM of six independent experiments performed in quadruplicate for each condition. *P < 0.05 versus medium (control), #P < 0.05 versus LPS (ANOVA followed by Bonferroni). ND = not detectable.

and B7.1/B7.2 play important roles in the migration and activation of macrophages [21, 22]. We next evaluated whether pyrenocine A was able to modulate the expression of this molecules in macrophages in the presence of an inflammatory stimulus (LPS). LPS stimulation increased the expression of Mac-1 and B7.1 compared to unstimulated cells (Figure 5). Treatment of macrophages with pyrenocine A with both the pretreatment and posttreatment procedures diminished the amount of B7.1 and Mac-1 on the cell surface measured by median intensity fluorescence (MIF) compared to macrophages stimulated with LPS alone. As shown in Figure 5(a), the pretreatment protocol with pyrenocine A inhibited the expression of Mac-1 at levels similar to unstimulated cells (without LPS). However, treatment with pyrenocine A in the presence of LPS resulted in only a modest inhibition of B7.2 expression on the surface of macrophages (data not shown).

3.5. The Suppressive Effects of Pyrenocine A Are Dependent on MyD88. LPS interacts with the CD14/LBP/TLR4 complex, resulting in the activation of MyD88-dependent and MyD88-independent pathways within a complex
biochemical cascade [1, 2]. To evaluate whether pyrenocine A exerts its anti-inflammatory effects through the MyD88-dependent and MyD88-independent pathways, we stimulated macrophages with two agonists: a TLR3 ligand (Poly I:C) and a TLR9 ligand (CpG-ODNs). Poly I:C promotes TLR3 activation via MyD88-independent pathway (by TRIF adapter molecule), while the binding of CpG to TLR9 induces MyD88-dependent activation. Then, we evaluate whether pyrenocine A exerts its anti-inflammatory effects by MyD88-independent or MyD88-dependent pathway using both agonists (Poly I:C and CpG-ODNs) as tools to suggest it. In the presence of CpG, the pretreatment and posttreatment with pyrenocine A on macrophages inhibited the synthesis of NO in a concentration-dependent manner when compared with CpG treatment alone (Figures 6(a) and 6(b)). However, in both pre- and posttreatment protocols, pyrenocine A was not able to inhibit NO synthesis when macrophages were stimulated with Poly I:C (Figures 6(c) and 6(d)).

3.6. Effects of Pyrenocine A on NF-κB-Dependent Gene Expression. We evaluated the expression of 43 genes, including cytokines, chemokines, or their receptors and components of the immune response, that are activated by NF-κB signaling in macrophages after treatment with high concentration of pyrenocine A using pretreatment and posttreatment protocols, in the presence of LPS. Gene expression was considered to be downregulated when the relative quantification (RQ) was less than 0.6 and upregulated when the RQ was more than 1.4 compared to the LPS group in the absence of pyrenocine A. The RQ was considered unchanged when the value was between 0.6 and 1.4. For most of the genes tested, there were no significant (P value < 0.05) differences in the mRNA levels (data not shown). However, the mRNA levels of the proinflammatory cytokine Tnf decreased significantly with the pretreatment procedure (Figure 7). Pyrenocine A also may exert anti-inflammatory effects by decreasing a specific mRNA of factors, such as Cxcl1, Ccl2, Bcl2, Icam1, Ptgis, and Thr2 in the pretreatment procedure (Figure 7), as well as Icam1 and Ilr in the posttreatment procedure (Figure 8). Additionally, pyrenocine A increases the mRNA levels of the anti-inflammatory cytokine Il10 in both the pretreatment and posttreatment protocols (Figures 7 and 8). Some genes were not amplified (data not shown), such as Vcam1, Il12a, and Ccl20, indicating that RAW264.7 macrophage cells are unable to transcribe these genes in response to LPS. Conversely, some proinflammatory genes were upregulated with the post-treatment treatment, such as Nos2, Il1a, Cd40 and Il12b, but not with the pretreatment treatment, suggesting that pretreatment procedure is able to downregulate proinflammatory genes in response to LPS (Figures 7 and 8).

4. Discussion

Although marine microorganisms are currently considered to be major natural sources of potently active secondary metabolites, very few natural products that have been isolated from marine microbes exhibit anti-inflammatory activity. Examples include salinamides A and B, which are depsipeptides produced by a marine streptomycete [23]; the cyclomarins, which are cyclic peptides that are also produced by a marine streptomycete [24]; lobophorins A and B, which are complex macrolides isolated from marine actinomycete cultures [25]; mangicols A and B, which are sesterterpenes isolated from the marine fungus Fusarium heterosporum [26]; and mycoepoxidiene, which is produced by a fungus in the genus Diaporthe [27]. Penstyrylpyrone, isolated from marine-derived Penicillium sp., was found to inhibit the synthesis of NO, PGE2, IL-1β, and TNF-α in peritoneal macrophages stimulated with LPS [28]. As microbial fermentation is a sustainable process, the search for new anti-inflammatory agents produced by marine microorganisms is an attractive strategy to facilitate the production of bioactive compounds.

To assess the anti-inflammatory profile of a specific compound, it is necessary to select a reliable approach. Our model
for this in vitro study, specifically utilizing macrophages stimulated with the inflammatory agent LPS, allows us to evaluate the effects of immunomodulatory compounds on soluble inflammatory signaling agents and cell surface receptors as well as to elucidate the mechanism of action to identify potential new inflammatory targets. The rationale of our approach is based on the fact that macrophages, which are resident cells that are distributed throughout different tissues in the body, play a key role in the inflammatory process and have a variety of cell surface receptors that permit strong interactions with PAMPs, which are present on the pathogen surfaces, as well as with DAMPS (damage-associated molecular pattern molecules) released by cells that enter necrosis. The results described here demonstrate that pyrenocine A, a secondary metabolite produced in liquid medium by the marine-derived fungus *Penicillium paxilli* Ma(G)K, exerts potent anti-inflammatory actions both pretreatment and posttreatment on cells that are part of the innate immune response.

The anti-inflammatory activity of pyrenocine A was initially assessed by ability to modulate nitric oxide production. Treatment of macrophages with pyrenocine A using both pretreatment and posttreatment procedures in the presence of the inflammatory stimulus LPS promoted strong concentration-dependent inhibition of NO production. Activated macrophages are present in injured tissues and are major producers of inflammatory mediators such as proinflammatory cytokines and lipid mediators, which have been implicated in the exacerbation and pathogenesis of acute and chronic inflammatory diseases [29]. Various steroidal and nonsteroidal (NSAIS) drugs have mechanisms of action that involve the inhibition of proinflammatory cytokine and chemokine production, including TNF-α, IL-1, IL-6, and IL-8.

**Figure 5:** Effects of pyrenocine A on the expression of Mac-1 and B7.2 by macrophages. Pretreatment procedure: cells were pretreated with different concentrations of pyrenocine A (3.75–0.94 μM) for 2 h and then stimulated with LPS (1 μg/mL) during 18 h. (b) Posttreatment procedure: cells were stimulated with LPS (1 μg/mL) for 2 h and then pyrenocine A was added (3.75–0.94 μM) during 18 h. The expression of surface receptors such as Mac-1 and B7.1 was evaluated by MIF and by measuring the percentage of positive cells, respectively. All samples were analyzed using flow cytometry and a FACSCanto machine with BD FACSDiva software. Results are representative of three independent experiments.
as well as the inhibition of NO synthesis [30]. Dexamethasone is a synthetic glucocorticoid with potent anti-inflammatory effects that is used as the first-line treatment for inflammatory diseases such as acute lung injury, asthma, and rheumatoid arthritis [31]. In addition to modulating inflammatory cytokines, some drugs have the ability to increase the synthesis of anti-inflammatory cytokines such as IL-10, which is a cytokine capable of indirectly mediating the synthesis of anti-inflammatory mediators, including various surface receptors [32]. Beside dexamethasone, compounds from plants, such as ursolic acid, have a potent anti-inflammatory effect on macrophages by promoting the inhibition of TNF-α, IL-1, and IL-6 from macrophages in the presence of LPS as well as costimulatory molecules (CD80 and CD86) in B cells and T cells proliferation. The suppressive effect of ursolic acid is mediated, at least in lymphocytes, by the inhibition of nuclear translocation of NF-κB, NF-AT, and AP-1 translocation into the nucleus. [33]. The results presented here demonstrate that pyrenocine A has both pretreatment and posttreatment anti-inflammatory effects on the synthesis of TNF-α and PGE2 by macrophages stimulated with LPS. Treatment with pyrenocine A did not induce increased IL-10 release, regardless of the concentration and protocol used. Although pyrenocine A did not induce statistically significant differences for IL-10 synthesis, both the pretreatment and posttreatment procedure in the presence of LPS increased the mRNA expression of IL-10. These results suggest that the kinetics of IL-10 mRNA expression and protein production may explain these contradictory results.

The recruitment of inflammatory cells to injured tissues is mediated by chemoattractants and adhesion-promoting agents such as integrins (CD11b/CD18), selectins (L-selectin), and chemokines [34]. Proinflammatory macrophages promote the recruitment and activation of neutrophils through
the release of cytokines and chemokines and the expression of surface molecules such as selectins and integrins as well as the subsequent recruitment of adaptive immune response cells. Such soluble inflammatory mediators or stimuli can also modulate the expression of costimulatory molecules on dendritic cells such as B7.1 and B7.2, which are essential for T cell activation. The expression of Mac-1 on macrophages is important not only for cellular recruitment of monocytes, cell-cell contact, and activation, but also for microbial phagocytosis [35]. Our results indicate that the pretreatment and posttreatment procedure with pyrenocine A promoted the decrease of expression of the surface receptors Mac-1 and B7.1 but only induced a slight decrease in B7.2 expression. Thus, pyrenocine A inhibits cytokine synthesis and also inhibits the expression of surface receptors involved in both cell recruitment and in the activation of leucocytes. Additionally, pyrenocine A inhibits macrophage mediators that reduce the recruitment of inflammatory cells to injured tissue, thereby contributing to disease chronicity.

Soluble mediators produced by inflammatory macrophages provide the microenvironment necessary for the recruitment of inflammatory cells such as neutrophils,
macrophages, and autoreactive T lymphocytes. Substantial amounts of NO and prostaglandin E2 (PGE2) are produced during the inflammatory process by iNOS and cyclooxygenase 2 (COX-2) [36]. Pyrenocine A was able to inhibit PGE2 synthesis with the pretreatment protocol but only modestly inhibited synthesis with the posttreatment approach. Similarly, Pges, one of the major enzymes involved in the synthesis of PGE2, was also inhibited when macrophages were treated with pyrenocine A using the pretreatment protocol but not the posttreatment protocol.

To assess the molecular mechanism involved in pyrenocine A anti-inflammatory actions, macrophages were stimulated with a TLR3 agonist (Poly I:C) and a TLR9 agonist (CpG-ODNs) to evaluate the MyD88-independent and MyD88-dependent signaling pathways, respectively. Since there was no suppression of nitrite production by TLR3/Poly I:C, we speculated that the suppressive effect of pyrenocine A on macrophages may be mediated by a MyD88-dependent pathway. It appears that the suppressive effects of pyrenocine A are selective, as it is able to inhibit a specific biochemical
cascade and promote the suppressive actions of specific inflammatory stimuli. When we analyzed the effects of pyrenocine A on the modulation of NFκB-dependent gene expression, we observed that pyrenocine A promoted the inhibition of genes such as Cxcl1, Ccl2, Icam1, and Tlr2 with the pretreatment procedure and Icam1 and Ilr with the posttreatment procedure in addition to inhibiting Tnf and Ptgases mRNA expression. Conversely, pyrenocine A increased the mRNA expression of the anti-inflammatory cytokine Il-10, both before treatment and after treatment. Our results suggest that pyrenocine A can downmodulate the expression of additional genes that are involved in the chemotaxis of inflammatory cells (Cxcl1, Ccl2) and an integrin involved in recruitment and cell activation (Icam).

Together, our findings suggest that pyrenocine A has a potential anti-inflammatory effect on cells from innate immune response; however, the potential prophylactic and therapeutic applications of pyrenocine A need to evaluate in vivo inflammatory murine model.

5. Conclusions

In conclusion, we demonstrated that pyrenocine A, which was produced in the culture media of the marine-derived fungus *Penicillium paxilli* Ma(G)K, promotes immunosuppressive effects via the inhibition of proinflammatory mediators (TNF-α and PGE2) and the expression of molecules involved in cell migration (Mac-1) and T cell activation (B7.1). Our results suggest that pyrenocine A inhibits macrophage activation, probably by interfering with the MyD88-dependent pathway but not through the TRIF signaling pathway. Pyrenocine A is able to inhibit the expression of genes related to NFκB activation in macrophages stimulated with LPS. Our findings indicate that pyrenocine A is novel compound with immunosuppressive properties.

Conflict of Interests

The authors declare no conflict of interests.

Authors’ Contributions

A. I. Medeiros and N. N. Dejani participated in research design. N. N. Dejani, T. R. Toledo, L. G. S. Monnazzi, and M. H. Kossuga conducted experiments. R. G. S. Berlink contributed to the new reagents or analytical tools. L. G. S. Monnazzi, N. N. Dejani, T. R. Toledo, R. G. S. Berlink, L. D. Sette, and A. I. Medeiros performed data analysis. R. G. S. Berlink, A. I. Medeiros, and L. D. Sette wrote or contributed to the writing of the paper. T. R. Toledo and N. N. Dejani equally contributed to this work.

Acknowledgments

This work was supported by the Fundação de Amparo a Pesquisas do Estado de São Paulo, Brazil (FAPESP 2010/50190-2); the Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (CNPq, 302097/2010-4); and the Coordenção de Aperfeiçoamento de Pessoal de Nível Superior (CAPES-PROEX). Miriam H. Kossuga thanks FAPESP for a postdoctoral scholarship (2008/00331-9). The funding agencies had no role in the study design, data collection, and analysis; the decision to publish; or preparation of the paper.

References

[1] B. A. Beutler, “TLRs and innate immunity,” *Blood*, vol. 113, no. 7, pp. 1399–1407, 2009.
[2] R. Medzhitov, “Recognition of microorganisms and activation of the immune response,” *Nature*, vol. 449, no. 7164, pp. 819–826, 2007.
[3] B. S. Park, D. H. Song, H. M. Kim, B.-S. Choi, H. Lee, and J.-O. Lee, “The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex,” *Nature*, vol. 458, no. 7242, pp. 1191–1195, 2009.
[4] S.-F. Chang, B.-H. Chou, L.-M. Yang et al., “Microbial transformation of isosteviol oxime and the inhibitory effects on NF-kB and AP-1 activation in LPS-stimulated macrophages,” *Bioorganic & Medicinal Chemistry*, vol. 17, no. 17, pp. 6348–6353, 2009.
[5] S. Shin, S. S. Joo, D. Park et al., “Ethanol extract of *Angelica gigas* inhibits croton oil-induced inflammation by suppressing the cyclooxygenase—prostaglandin pathway,” *Journal of Veterinary Science*, vol. 11, no. 1, pp. 43–50, 2010.
[6] J. M. McCoy, J. R. Wicks, and L. P. Audoly, “The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis,” *The Journal of Clinical Investigation*, vol. 110, no. 5, pp. 651–658, 2002.
[7] T. G. Brock, R. W. McNish, P. Mancuso, M. J. Coffey, and M. Peters-Golden, “Prolonged lipopolysaccharide inhibits leukotriene synthesis in peritoneal macrophages: mediation by nitric oxide and prostaglandins,” *Prostaglandins & Other Lipid Mediators*, vol. 71, no. 3-4, pp. 131–145, 2003.
[8] N. Gualde and H. Harizi, “Prostanoids and their receptors that modulate dendritic cell-mediated immunity,” *Immunology & Cell Biology*, vol. 82, no. 4, pp. 353–360, 2004.
[9] Y. Sugimoto, Y. Fukada, D. Mori et al., “Prostaglandin E2 stimulates granulocyte colony-stimulating factor production via the prostaglandin EP2 receptor in mouse peritoneal neutrophils,” *The Journal of Immunology*, vol. 175, no. 4, pp. 2606–2612, 2005.
[10] B. Sastre and V. del Pozo, “Role of PGE2 in asthma and nonasthmatic eosinophilic bronchitis,” *Mediators of Inflammation*, vol. 2012, Article ID 645383, 9 pages, 2012.
[11] A. Amedei and M. M. D’Eliaos, “New therapeutic approaches by using microorganism-derived compounds,” *Current Medicinal Chemistry*, vol. 19, no. 22, pp. 3822–3840, 2012.
[12] J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro, and M. R. Prinsep, “Marine natural products,” *Natural Product Reports*, vol. 30, no. 2, pp. 237–323, 2013.
[13] C. C. Hughes and W. Fenical, “Antibacterials from the sea,” *Chemistry A*, vol. 16, no. 42, pp. 12512–12525, 2010.
[14] R. Ebel, “Terpenes from marine-derived fungi,” *Marine Drugs*, vol. 8, no. 8, pp. 2340–2368, 2010.
[15] M. E. Rateb and R. Ebel, “Secondary metabolites of fungi from marine habitats,” *Natural Product Reports*, vol. 28, no. 2, pp. 290–344, 2011.
[16] M. Saleem, S. M. Ali, S. Hussain, A. Jabbar, M. Ashraf, and Y. S. Lee, “Marine natural products of fungal origin,” *Natural Product Reports*, vol. 24, no. 5, pp. 1142–1152, 2007.
[17] C. Nilanonta, M. Isaka, P. Kittakoop et al., “New diketopiperazines from the entomopathogenic fungus *Verticillium hemipterigenum* BCC 1449,” *The Journal of Antibiotics*, vol. 56, no. 7, pp. 647–651, 2003.

[18] M. H. Kossuga, S. Romminger, C. Xavier et al., “Evaluating methods for the isolation of marine-derived fungal strains and production of bioactive secondary metabolites,” *Revista Brasileira de Farmacognosia*, vol. 22, no. 2, pp. 257–267, 2012.

[19] T. E. Lane, B. A. Wu-Hsieh, and D. H. Howard, “Gamma interferon cooperates with lipopolysaccharide to activate mouse splenic macrophages to an antihistoplasma state,” *Infection and Immunity*, vol. 61, no. 4, pp. 1468–1473, 1993.

[20] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-ΔΔC_T} method,” *Methods*, vol. 25, no. 4, pp. 402–408, 2001.

[21] S. Ghosh and R. K. Saxena, “Early effect of *Mycobacterium tuberculosis* infection on Mac-1 and ICAM-1 expression on mouse peritoneal macrophages,” *Experimental & Molecular Medicine*, vol. 36, no. 5, pp. 387–395, 2004.

[22] J. Y. Lee, M. H. Rhee, and J. Y. Cho, “Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells,” *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 377, no. 2, pp. 111–124, 2000.

[23] J. A. Trischman, D. M. Tapiolas, P. R. Jensen et al., “Salinamides A and B: anti-inflammatory depsipeptides from a marine streptomycete,” *Journal of the American Chemical Society*, vol. 116, no. 2, pp. 757–758, 1994.

[24] M. K. Renner, Y.-C. Shen, X.-C. Cheng et al., “Cyclomarins A-C, new antiinflammatory cyclic peptides produced by a marine bacterium (*Streptomyces* sp.),” *Journal of the American Chemical Society*, vol. 121, no. 49, pp. 11273–11276, 1999.

[25] Z.-D. Jiang, P. R. Jensen, and W. Fenical, “Lobophorins A and B, new antiinflammatory macrolides produced by a tropical marine bacterium,” *Bioorganic & Medicinal Chemistry Letters*, vol. 9, no. 14, pp. 2003–2006, 1999.

[26] J. Li, H.-C. Hsu, and J. Mountz, “Managing macrophages in rheumatoid arthritis by reform or removal,” *Current Rheumatology Reports*, vol. 14, no. 5, pp. 445–454, 2012.

[27] C.-H. Hsing, M.-C. Lin, P.-C. Choi et al., “Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen species-regulated Akt/IKKβ/NF-κB signaling,” *PLoS ONE*, vol. 6, no. 3, Article ID e17598, 2011.